BRIUMVI Momentum + Selective Buybacks: A Tactical Long on TGTX
TG Therapeutics' BRIUMVI continues to drive outsized top-line growth, management is leaning into commercial expansion and awareness campaigns, and the stock trades at a reasonable P/E for a growth-to-profit story. We recommend a tactical long with a $33.20 entry, $46.48 target and $29.00 stop, horizon ~180 trading days.